S. 113 · 118th Congress

Prescription Pricing for the People Act of 2023

Introduced on Jan 26, 2023 by Chuck Grassley (R-IA). 21 cosponsors, 10 of them from another party. Latest action (Mar 1, 2023): Placed on Senate Legislative Calendar under General Orders. Calendar No. 19.

Stage
Reported by committee
Introduced
Jan 26, 2023
Cosponsors
21
10 from the other party
Policy area
Commerce
Open in the Congress explorerCongress.govAlert me

Progress

The furthest stage the measure reached. Simple and concurrent resolutions do not go to the President.

  1. Introduced
  2. Reported by committee
  3. 3Passed one chamber
  4. 4Passed both chambers
  5. 5Sent to the President
  6. 6Became law

Official title

A bill to require the Federal Trade Commission to study the role of intermediaries in the pharmaceutical supply chain and provide Congress with appropriate policy recommendations, and for other purposes.

Subjects

  • Business ethics
  • Business records
  • Competition and antitrust
  • Congressional oversight
  • Consumer affairs
  • Health care costs and insurance
  • Health information and medical records
  • Inflation and prices
  • Prescription drugs
  • Retail and wholesale trades

Summary

The Congressional Research Service has not summarized this measure yet.

Sponsor and cosponsors

Cosponsors by party as of the day they signed on. Original cosponsors signed on the day of introduction.

Chuck GrassleyR-IASponsor

Democrats · 10

Independents · 1

Republicans · 10

Roll calls

Recorded votes on the measure. Most measures move by voice vote or unanimous consent, which record no individual positions.

No recorded roll call on this measure: it moved by voice vote or unanimous consent, or has not reached the floor.

History

Every action as published, oldest first. Roll calls link to how each member voted.

  1. Jan 26, 2023Introduced in Senate
  2. Jan 26, 2023 · SenateRead twice and referred to the Committee on the Judiciary.
  3. Feb 9, 2023 · SenateCommittee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.
  4. Mar 1, 2023Committee on the Judiciary. Reported by Senator Durbin with an amendment in the nature of a substitute. Without written report.
  5. Mar 1, 2023 · SenateCommittee on the Judiciary. Reported by Senator Durbin with an amendment in the nature of a substitute. Without written report.
  6. Mar 1, 2023 · SenatePlaced on Senate Legislative Calendar under General Orders. Calendar No. 19.

Committees

Committees and subcommittees the measure was referred to.

Agencies in its committees' jurisdiction

Analisa's mapping of committee jurisdiction to federal agencies; the bill may touch others, or none of these.

Who lobbied on it

Organizations whose lobbying reports (LD-2) name this measure. Spending is what they reported for those quarters on all issues, not on this measure alone.

  1. PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA10 reports
    $37.4M reported (all issues)
  2. TEVA PHARMACEUTICALS USA, INC.6 reports
    $2.5M reported (all issues)Federal contractor: TEVA PHARMACEUTICALS USA, INC.$25.9M in contracts, FY2026AI match · 100%
  3. AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP)5 reports
    $14.2M reported (all issues)
  4. AMERICAN INTELLECTUAL PROPERTY LAW ASSOCIATION (AIPLA)5 reports
    $10K reported (all issues)
  5. AMGEN INC.5 reports
    $15.2M reported (all issues)Federal contractor: AMGEN INC.AI match · 99%
  6. American Medical Association5 reports
    $30.1M reported (all issues)Federal contractor: AMERICAN MEDICAL ASSOCIATION$371K in contracts, FY2026AI match · 99%
  7. Amgen USA, Inc.5 reports
    $300K reported (all issues)Federal contractor: AMGEN USA INC$126M in contracts, FY2026AI match · 100%
  8. BIOTECHNOLOGY INNOVATION ORGANIZATION5 reports
    $8.9M reported (all issues)
  9. CROHN'S & COLITIS FOUNDATION5 reports
    $240K reported (all issues)
  10. Cencora Inc. (formerly AmerisourceBergen Corporation)5 reports
    $100K reported (all issues)
  11. Fresenius Kabi USA LLC5 reports
    Federal contractor: FRESENIUS KABI USA, LLCAI match · 100%
  12. GENENTECH INC.5 reports
    Federal contractor: GENENTECH USA, INC$939.6K in contracts, FY2026AI match · 100%
  13. GSK (fka GLAXOSMITHKLINE INC.)5 reports
    $6.3M reported (all issues)
  14. NATIONAL ASSOCIATION OF CHAIN DRUG STORES, INC.5 reports
    $4.2M reported (all issues)
  15. NATIONAL COMMUNITY PHARMACISTS ASSOCIATION5 reports
    $1.8M reported (all issues)Federal contractor: NATIONAL COMMUNITY PHARMACISTS ASSOCIATIONAI match · 100%
  16. NATIONAL MULTIPLE SCLEROSIS SOCIETY5 reports
    $319.3K reported (all issues)
  17. PFIZER INC.5 reports
    Federal contractor: PFIZER INCAI match · 100%
  18. Pharmaceutical Industry Labor-Management Association5 reports
    $140K reported (all issues)
  19. Sanofi U.S. Services, Inc.5 reports
    $300K reported (all issues)
  20. The Cigna Group and subsidiaries (Formerly Cigna Corporation5 reports
    $10.2M reported (all issues)
  21. NOVARTIS CORPORATION4 reports
    $6M reported (all issues)Federal contractor: NOVARTIS PHARMACEUTICALS CORPORATION$36.2M in contracts, FY2026AI match · 100%
  22. PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION4 reports
    $17.8M reported (all issues)
  23. Pharmaceutical Industry Labor Management Association (PILMA)4 reports
    $60K reported (all issues)
  24. The Leukemia & Lymphoma Society4 reports
    $1M reported (all issues)
  25. AARP3 reports
    $14.7M reported (all issues)
  26. ELEVANCE HEALTH, INC.3 reports
    $3.8M reported (all issues)
  27. Families USA Foundation, Inc.3 reports
    $26K reported (all issues)
  28. Cigna Corporation2 reports
    $180K reported (all issues)Federal contractor: CIGNA WORLDWIDE INSURANCE BRANCH$2.5M in contracts, FY2026AI match · 99%
  29. Healthcare Distribution Alliance (FORMERLY - HDMA)1 report
    $604.6K reported (all issues)
  30. Healthcare Distribution Alliance (Healthcare Distribution Managment Assn.)1 report
    $80K reported (all issues)
  31. Public Citizen1 report
    $73.3K reported (all issues)
  32. TAKEDA PHARMACEUTICALS AMERICA, INC.1 report
    $970K reported (all issues)Federal contractor: TAKEDA PHARMACEUTICALS AMERICA, INC.$1.6M in contracts, FY2026AI match · 100%

Reports filed in 2023, 2024.

Sources and method

Every figure on this page traces to these records.

  • Bill status: bills and resolutions, sponsors, actions, subjects and CRS summaries (U.S. Government Publishing Office (GovInfo), from Congress.gov (Library of Congress))GovInfo Bill Status bulk data (Congress.gov; summaries by the Congressional Research Service) · data current to Oct 6, 2026 · loaded Oct 6, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Members of Congress, their terms, committees and identifiers (The @unitedstates project (from the Biographical Directory of the U.S. Congress, the House and the Senate))unitedstates/congress-legislators: legislators, committees and current committee membership · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: CC0 1.0 (public domain dedication)
  • House roll-call votes (Office of the Clerk, U.S. House of Representatives)Office of the Clerk, U.S. House of Representatives, roll-call vote records · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Senate roll-call votes and DW-NOMINATE scores (Voteview (UCLA Department of Political Science))Lewis, Jeffrey B., Keith Poole, Howard Rosenthal, Adam Boche, Aaron Rudkin, and Luke Sonnet (2026). Voteview: Congressional Roll-Call Votes Database. https://voteview.com/ · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Free to use with the required citation
  • Lobbying disclosures (LD-1 registrations, LD-2 quarterly reports, LD-203 contribution reports) (Clerk of the U.S. House of Representatives)Clerk of the House, Lobbying Disclosure Act filings (organizations only; lobbyists' names are not loaded) · data current to Oct 6, 2026 · loaded Oct 6, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Positions are shown only where a roll call recorded them; voice votes and unanimous consent record none.
  • Money and votes are shown side by side; neither explains the other.